191 related articles for article (PubMed ID: 6447930)
1. Characterization of dermatan sulfate and heparan sulfate in the urine of a patient with the Hunter syndrome.
Kimura A; Hayashi S; Tsurumi K
Tohoku J Exp Med; 1980 Jul; 131(3):227-39. PubMed ID: 6447930
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of urinary glycosaminoglycans excreted by a patient with the Hurler-Scheie compound syndrome.
Kimura A; Hayashi S; Koseki M; Tsurumi K
Tohoku J Exp Med; 1982 Jan; 136(1):61-6. PubMed ID: 6803394
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of peptidoglycans in urine from patients with mucopolysaccharidoses.
Tanaka Y; Takazono I
Int J Biochem; 1984; 16(5):435-46. PubMed ID: 6233194
[TBL] [Abstract][Full Text] [Related]
4. Separation of dermatan sulfate from heparan sulfate in mucopolysaccharidosis urine by chromatography on Sephadex G-75.
Herd JK; Forrest T; Tschida J
Clin Chim Acta; 1976 Apr; 68(1):1-9. PubMed ID: 131009
[TBL] [Abstract][Full Text] [Related]
5. Chemical definition of the mucopolysaccharidoses.
Constantopoulos G; Dekaban AS
Clin Chim Acta; 1975 Mar; 59(3):321-36. PubMed ID: 123832
[TBL] [Abstract][Full Text] [Related]
6. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
[TBL] [Abstract][Full Text] [Related]
7. Chemical structure of urinary dermatan sulfate excreted by a patient with the Hunter syndrome.
Kimura A; Hayashi S; Tsurumi K
Tohoku J Exp Med; 1980 Jul; 131(3):241-7. PubMed ID: 6774445
[TBL] [Abstract][Full Text] [Related]
8. The heterogeneity of dermatan sulfate and heparan sulfate in rat liver and a shift in the glycosaminoglycan contents in carbon tetrachloride-damaged liver.
Suzuki S; Suzuki S; Nakamura N; Koizumi T
Biochim Biophys Acta; 1976 Mar; 428(1):166-181. PubMed ID: 130930
[TBL] [Abstract][Full Text] [Related]
9. Comparative structural studies of urinary glycosaminoglycans in the Hurler and Hunter syndromes.
Ramage P; Cunningham WL
Biochim Biophys Acta; 1975 Dec; 411(2):325-33. PubMed ID: 127616
[TBL] [Abstract][Full Text] [Related]
10. Mucopolysaccharidoses type II: enzymatic activity and quantitative and qualitative studies of urinary glycosaminoglycans in five patients.
Gallegos-Arreola MP; González-Noriega A; Zúñiga-González GM; Flores-Martínez SE; Morán Moguel MC; Figuera LE; Sánchez-Corona J
Arch Med Res; 1997; 28(1):91-4. PubMed ID: 9078594
[TBL] [Abstract][Full Text] [Related]
11. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses.
Zhang H; Wood T; Young SP; Millington DS
Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519
[TBL] [Abstract][Full Text] [Related]
12. Changes in cat urinary glycosaminoglycans with age and in feline urologic syndrome.
Pereira DA; Aguiar JA; Hagiwara MK; Michelacci YM
Biochim Biophys Acta; 2004 Apr; 1672(1):1-11. PubMed ID: 15056487
[TBL] [Abstract][Full Text] [Related]
13. The effect of fasting and time of day on the urinary excretion of chondroitin 4/6 sulphate, dermatan sulphate and four chondroitinase ABC resistant glycosaminoglycans.
Poulsen JH; Gregersen H
Scand J Clin Lab Invest; 1983 Dec; 43(8):665-70. PubMed ID: 6420878
[TBL] [Abstract][Full Text] [Related]
14. Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus.
Cadaval RA; Kohlman O; Michelacci YM
Glycobiology; 2000 Feb; 10(2):185-92. PubMed ID: 10642610
[TBL] [Abstract][Full Text] [Related]
15. A defect in exodegradative pathways provides insight into endodegradation of heparan and dermatan sulfates.
Fuller M; Chau A; Nowak RC; Hopwood JJ; Meikle PJ
Glycobiology; 2006 Apr; 16(4):318-25. PubMed ID: 16377754
[TBL] [Abstract][Full Text] [Related]
16. Polydispersity of glycosaminoglycans in normal human urine.
Endo M; Namiki O; Yosizawa Z
Tohoku J Exp Med; 1980 Aug; 131(4):327-37. PubMed ID: 6781104
[TBL] [Abstract][Full Text] [Related]
17. Differences in the nonreducing ends of heparan sulfates excreted by patients with mucopolysaccharidoses revealed by bacterial heparitinases: a new tool for structural studies and differential diagnosis of Sanfilippo's and Hunter's syndromes.
Toma L; Dietrich CP; Nader HB
Lab Invest; 1996 Dec; 75(6):771-81. PubMed ID: 8973472
[TBL] [Abstract][Full Text] [Related]
18. Molecular size difference of urinary heparan sulfates from normal individuals and genetic mucopolysaccharidoses.
Taniguchi N; Miyawaki T; Moriya N; Okuda N
Clin Chim Acta; 1975 May; 60(3):363-9. PubMed ID: 124636
[TBL] [Abstract][Full Text] [Related]
19. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.
de Ru MH; van der Tol L; van Vlies N; Bigger BW; Hollak CE; Ijlst L; Kulik W; van Lenthe H; Saif MA; Wagemans T; van der Wal WM; Wanders RJ; Wijburg FA
J Inherit Metab Dis; 2013 Mar; 36(2):247-55. PubMed ID: 22991166
[TBL] [Abstract][Full Text] [Related]
20. Interaction of high molecular weight chondroitin sulfate from human aorta with plasma low density lipoproteins.
Alves CS; Mourão PA
Atherosclerosis; 1988 Oct; 73(2-3):113-24. PubMed ID: 3142491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
